Follow
Aziz Nazha
Aziz Nazha
Lerner College of Medicine/Case Western Reserve University
Verified email at ccf.org
Title
Cited by
Cited by
Year
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
F Ravandi, ML Alattar, MR Grunwald, MA Rudek, T Rajkhowa, MA Richie, ...
Blood, The Journal of the American Society of Hematology 121 (23), 4655-4662, 2013
4422013
Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic …
MA Sekeres, M Othus, AF List, O Odenike, RM Stone, SD Gore, MR Litzow, ...
Journal of Clinical Oncology 35 (24), 2745, 2017
2362017
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
D Haase, KE Stevenson, D Neuberg, JP Maciejewski, A Nazha, ...
Leukemia 33 (7), 1747-1758, 2019
2162019
Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes
A Nazha, M Narkhede, T Radivoyevitch, DJ Seastone, BJ Patel, AT Gerds, ...
Leukemia 30 (11), 2214-2220, 2016
1692016
Phase I/II trial of the combination of midostaurin (PKC412) and 5‐azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome
P Strati, H Kantarjian, F Ravandi, A Nazha, G Borthakur, N Daver, T Kadia, ...
American journal of hematology 90 (4), 276-281, 2015
1682015
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities
P Jain, H Kantarjian, A Nazha, S O’Brien, E Jabbour, CG Romo, S Pierce, ...
Blood, The Journal of the American Society of Hematology 121 (24), 4867-4874, 2013
1682013
hnRNP K is a haploinsufficient tumor suppressor that regulates proliferation and differentiation programs in hematologic malignancies
M Gallardo, HJ Lee, X Zhang, C Bueso-Ramos, LR Pageon, M McArthur, ...
Cancer cell 28 (4), 486-499, 2015
1452015
Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer
RJ Molenaar, S Sidana, T Radivoyevitch, AS Advani, AT Gerds, ...
Journal of clinical oncology 36 (18), 1831, 2018
1352018
An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies
E Padron, G Garcia-Manero, MM Patnaik, R Itzykson, T Lasho, A Nazha, ...
Blood cancer journal 5 (7), e333-e333, 2015
1322015
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort
M Stahl, M DeVeaux, T De Witte, J Neukirchen, MA Sekeres, AM Brunner, ...
Blood advances 2 (14), 1765-1772, 2018
1222018
Measuring the symptom burden associated with the treatment of chronic myeloid leukemia
LA Williams, AGG Gonzalez, P Ault, TR Mendoza, ML Sailors, JL Williams, ...
Blood, The Journal of the American Society of Hematology 122 (5), 641-647, 2013
1162013
Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells
F Pan, TS Wingo, Z Zhao, R Gao, H Makishima, G Qu, L Lin, M Yu, ...
Nature communications 8 (1), 15102, 2017
1152017
Somatic mutations in MDS patients are associated with clinical features and predict prognosis independent of the IPSS-R: analysis of combined datasets from the International …
R Bejar, E Papaemmanuil, T Haferlach, G Garcia-Manero, JP Maciejewski, ...
Blood, The Journal of the American Society of Hematology 126 (23), 907-907, 2015
1102015
Personalized prediction model to risk stratify patients with myelodysplastic syndromes
A Nazha, R Komrokji, M Meggendorfer, X Jia, N Radakovich, J Shreve, ...
Journal of Clinical Oncology 39 (33), 3737, 2021
1052021
Genomic determinants of chronic myelomonocytic leukemia
BJ Patel, B Przychodzen, S Thota, T Radivoyevitch, V Visconte, ...
Leukemia 31 (12), 2815-2823, 2017
972017
Machine learning in haematological malignancies
N Radakovich, M Nagy, A Nazha
The Lancet Haematology 7 (7), e541-e550, 2020
952020
Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL)
SR Sanikommu, MJ Clemente, P Chomczynski, MG Afable, A Jerez, ...
Leukemia & lymphoma 59 (2), 416-422, 2018
952018
EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single …
E Jabbour, J Cortes, A Nazha, S O'Brien, A Quintas-Cardama, S Pierce, ...
Blood, The Journal of the American Society of Hematology 119 (19), 4524-4526, 2012
842012
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts
AM Zeidan, PC Boddu, MM Patnaik, JP Bewersdorf, M Stahl, RK Rampal, ...
The Lancet Haematology 7 (8), e601-e612, 2020
762020
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides
AM Zeidan, MA Sekeres, G Garcia-Manero, DP Steensma, K Zell, ...
Leukemia 30 (3), 649-657, 2016
712016
The system can't perform the operation now. Try again later.
Articles 1–20